Flash Radiotherapy for Skin Cancer
A phase 2 trial of FLASH radiotherapy in Cutaneous squamous cell carcinoma and Basal cell carcinoma, run by Jules Bordet Institute, not yet recruiting.
Overview
Flash Radiotherapy for Skin Cancer is a phase 2 interventional study registered as NCT07455331 by Jules Bordet Institute, with 60 participants planned, started 2026-06-23 and due to reach its primary completion in 2029-12-23. Interventions recorded: FLASH radiotherapy, Conventional radiotherapy. Conditions recorded: Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC).
Linked to the technology FLASH radiotherapy because the registry names it ("flash radiotherapy") among its interventions and Cutaneous squamous cell carcinoma and Basal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma and the tag pipeline.
- TrialClinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialPlacebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2/TNF in Patients With Basal Cell Carcinoma
Shares Basal cell carcinoma and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Shares Basal cell carcinoma and the tag pipeline.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Cutaneous squamous cell carcinoma and the tag pipeline.